Protein

Details Protein Protein

2008-05-13

2008-05-13

Woitach, Joseph (Department: 1633)

Drug, bio-affecting and body treating compositions

Enzyme or coenzyme containing

C514S002600, C435S007100, C536S023740, C424S094600

Reexamination Certificate

active

10503556

ABSTRACT:
A nucleic acid comprising a nucleotide sequence encoding a lysin, which nucleotide sequence comprises the sequence shown in SEQ ID No. 1 or a variant, homologue or derivative thereof. A novel lysin obtainable from a bacteriophage capable of colonisingClostridium perfringens, and the use thereof as a medicament for the treatment of a disorder associated with pathogenicClostridiumbacteria, for example.

REFERENCES:
patent: 6248324 (2001-06-01), Fischetti et al.
patent: 6254866 (2001-07-01), Fischetti et al.
patent: 0290295 (1988-11-01), None
patent: 0510907 (1992-10-01), None
patent: WO 00/11472 (2000-03-01), None
Loessner MJ, Gaeng S, Wendlinger G, Maier SK, Scherer S. The two-component lysis system ofStaphylococcus aureusbacteriophage Twort: a large TTG-start holin and an associated amidase endolysin. FEMS Microbiol Lett. May 15, 1998;162(2):265-74.
Songer JG. Clin Microbiol Rev. Clostridial enteric diseases of domestic animals. Apr. 1996;9(2):216-34.
Loessner MJ, Kramer K, Ebel F, Scherer S. C-terminal domains ofListeria monocytogenesbacteriophage murein hydrolases determine specific recognition and high-affinity binding to bacterial cell wall carbohydrates. Mol Microbiol. Apr. 2002;44(2):335-49.
Young R. Bacteriophage lysis: mechanism and regulation. Microbiol Rev. Sep. 1992;56(3):430-81.
Bowie, j et al., Deciphering the message in protein sequences: tolerance to amino acid substitutions.Science. 1990 ;247:1306-10.
STIC Protein Search Report. Tracking No. 171285, pp. 1-3.
Mims et al., 2004, Medical Microbiology, Third Edition, pp. 9-10, 474-475, 497.
Scientific Considerations Related to Developing Follo-On Protein Products. Division of Dockets Management U.S. Food and Drug Administration Nov. 12, 2004, pp. 1-12.
Mims et al., 2004, Medical Microbiology, Third Edition, Mosby, p. 593.
Gill et al., Bacteriophages and phage-derived products as antibacterial therapeutics.Expert Opinion on Therapeutic Patents Nov. 2007, vol. 17, No. 11, pp. 1341-1350.
Shimizu et al., “The virR gene, a member of a class of two-component response regulators, regulates the production of perfringolysin O, collagenase, and hemagglutinin inClostridium perfringens,” J. Bacteriology, 176:1616-1623, 1994.
Zimmer et al., “Genomic analysis ofClostridium perfringensbacteriophage phi3626, which integrates into guaA and possibly affects sporulation,”Journal of Bacteriology, 184(16):4359-4368, 2002.
Zimmer et al., “The murein hydrolase of the bacteriophage Φ3626 dual lysis system is active against all testedClostridium perfringensstrains,”Applied and Environmental Microbiology, 68(11):5311-5317, 2002.
Garnier et al., “Complete nucleotide sequence and genetic organization of the bacteriocinogenic plasmid, pIP404, fromClostridium perfringens,” Plasmid, 19:135-150, 1988.
GenBank Accesssion No. AB016282, Jul. 16, 1998.
Ishikawa et al., “Cloning and expression of two autolysin genes, cwIU and cwIV, which are tandemly arranged on the chromosome ofBacillus polymyxavar. colistimus,”Mol. Gen. Genet., 262:738-748, 1999.
Kunst et al., “The complete genome sequence of the Gram-positive bacteriumBacillus subtilis,” Nature, 390:249-256, 1997.
Loessner et al., “ThreeBacillus cereusbacteriophage endolysins are unrelated but reveal high homology to cell wall hydrolases from different bacilli,”J. Bacteriol., 179:2845-28551, 1997.
Lyristis et al., “Identification and molecular analysis of a locus that regulates extracellular toxin production inClostridium perfringens.,” Mol. Microbiol., 12:761-777, 1994.
Nakamura et al., “Clostridium perfringens-specific lysin,”Can. J. Microbiol., 23:601-606, 1977.
Cheng et al., “Removal of group Bstreptococcicolonizing the vagina and oropharynx of mice with a bacteriophage lytic enzyme,”Antimicrob. Agents Chemother., 49:111-117, 2005.
Loeffler et al., “Rapid Killing ofStreptococcus pneumoniaewith Bacteriophage Cell Wall Hydrolase,”Science, 294:2170-2172, 2001.
Nelson et al., “Prevention and elimination of upper respiratory colonization of mice by group A streptococci by using a bacteriophage lytic enzyme,”Proc. Natl. Acad. Sci. USA, 98:4107-4112, 2001.
Oldham and Daley, “Lysostaphin: Use of a Recombinant Bactericidal Enzyme as a Mastitis Therapeutic,”J. Dairy Science, 74:4175-4182, 1991.
Rodriguez-Cerrato et al., “Pneumococcal LytA autolysin, a potent therapeutic agent in experimental peritonitis-sepsis caused by highly beta-lactam-resistantStreptococcus pneumoniae,” Antimicrob. Agents Chemother., 51:3371-3373, 2007.
Schuch et al., “A bacteriolytic agent that detects and killsBacillus anthracis,” Nature, 418:884-889, 2002.

Affiliated with

Also associated with

Rating

Protein does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Protein, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Protein will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3940525